Dr. Linquan Tang 唐林泉
Chief Physician
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Screening, diagnosis, and treatment of early nasopharyngeal carcinoma. Chemoradiotherapy for locally advanced cases. Chemotherapy, targeted therapy, SBRT, and immunotherapy for recurrent or metastatic disease. AI-assisted diagnosis and efficacy prediction.
Dr. Tang holds a PhD in Oncology from Sun Yat-sen University (2015). As an Associate Chief Physician and doctoral supervisor, Dr. Tang focuses on precision diagnosis and treatment of nasopharyngeal carcinoma. Research findings have been incorporated into five international guidelines. Dr. Tang has published over 50 SCI papers as corresponding or first author.
Professional roles
- Standing Committee Member, Radioimmunology Youth Committee, China Cancer Radiotherapy Alliance
- Secretary, Tumor Microenvironment Professional Committee, China Anti-Cancer Association
- Youth Committee Member, Tumor Marker Committee, China Anti-Cancer Association
- Standing Committee Member, Nasopharyngeal Carcinoma Precision Treatment Professional Committee, Guangdong Clinical Medical Association
Name order: in Chinese the family name comes first (Tang Linquan). Papers usually list the name as Linquan Tang or Tang L.
Selected publications
182 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Gut, 2026 (senior author): Metagenomic identification of gut microbiome signatures for accurate diagnosis and prognostic prediction of Epstein-Barr virus-associated nasopharyngeal carcinoma. PubMed 42049488
- Eur J Nucl Med Mol Imaging, 2026 (senior author): [(18)F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinoma. PubMed 41032079
- EClinicalMedicine, 2025 (senior author): Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trial. PubMed 41245547
- Eur J Radiol, 2025 (senior author): Potential values of uEXPLORER total-body PET/CT in nasopharyngeal carcinoma: dynamic imaging and kinetic parameters. PubMed 40974693
- Clin Cancer Res, 2025 (first author): GFH018 and Toripalimab Combination Therapy for Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: Results from a Phase Ib/II Study. PubMed 40512241
- J Magn Reson Imaging, 2024 (senior author): Modulation Effects of the CEP128 Gene on Radiotherapy-Related Brain Injury: A Longitudinal Structural Study Using Multi-Parametric Brain MR Images. PubMed 37249021
- BMC Med, 2023 (senior author): Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter study. PubMed 38012705
- Eur Radiol, 2023 (senior author): Head and neck MRI-based T stage and [(18)F]FDG PET/CT-based N/M stage improved prognostic stratification in primary nasopharyngeal carcinoma. PubMed 37314471
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion